{"nctId":"NCT01217606","briefTitle":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2011-01"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"count":185,"armGroups":[{"label":"Triple Combination Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)"]},{"label":"Combigan®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution"]}],"interventions":[{"name":"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","otherNames":[]},{"name":"Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","otherNames":["COMBIGAN®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ocular hypertension or primary open-angle glaucoma in each eye\n* Requires treatment with IOP-lowering medication in both eyes\n\nExclusion Criteria:\n\n* Required chronic use of ocular medications during the study other than study medication\n* Use of any corticosteroids within 30 days\n* History of any traumatic eye surgeries\n* Cataract surgery in the past 6 months\n* Anticipated wearing of contact lenses during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test","description":"Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed using a two-sample t-test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.42","spread":"2.902"},{"groupId":"OG001","value":"24.43","spread":"2.592"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.45","spread":"3.175"},{"groupId":"OG001","value":"-8.28","spread":"3.256"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure","description":"Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) Hour 0 IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by a mixed-effect model for repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.42","spread":"2.902"},{"groupId":"OG001","value":"24.43","spread":"2.592"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.63","spread":"3.060"},{"groupId":"OG001","value":"-8.13","spread":"2.969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.24","spread":"3.283"},{"groupId":"OG001","value":"-8.12","spread":"2.942"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.88","spread":"3.193"},{"groupId":"OG001","value":"-8.35","spread":"3.100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.53","spread":"3.165"},{"groupId":"OG001","value":"-7.94","spread":"3.453"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.56","spread":"3.224"},{"groupId":"OG001","value":"-8.16","spread":"3.161"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.41","spread":"2.976"},{"groupId":"OG001","value":"-8.29","spread":"3.221"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.29","spread":"3.275"},{"groupId":"OG001","value":"-8.14","spread":"2.937"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.38","spread":"3.398"},{"groupId":"OG001","value":"-7.58","spread":"3.486"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)","description":"Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP is evaluated at Hour 0 and Hour 2 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. The mean of Hours 0 and 2 is calculated at Baseline and Week 12 in the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are analyzed by ANCOVA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.42","spread":"2.902"},{"groupId":"OG001","value":"24.43","spread":"2.592"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.63","spread":"3.060"},{"groupId":"OG001","value":"-8.13","spread":"2.969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.20","spread":"3.290"},{"groupId":"OG001","value":"-8.28","spread":"3.076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.85","spread":"3.180"},{"groupId":"OG001","value":"-8.53","spread":"3.228"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.44","spread":"3.105"},{"groupId":"OG001","value":"-8.07","spread":"3.521"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.45","spread":"3.175"},{"groupId":"OG001","value":"-8.28","spread":"3.256"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.32","spread":"2.965"},{"groupId":"OG001","value":"-8.42","spread":"3.252"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.09","spread":"3.349"},{"groupId":"OG001","value":"-8.17","spread":"3.031"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.36","spread":"3.368"},{"groupId":"OG001","value":"-7.77","spread":"3.489"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Conjunctival hyperaemia","Punctate keratitis","Blepharitis","Conjunctival follicles","Eye pruritus"]}}}